CHRISTOPHER HOOPER GOSS

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. doi request reprint Comparative effectiveness research - what is it and how does one do it?
    Christopher H Goss
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington, Seattle, WA, USA Division of Pulmonary Medicine, Department of Pediatrics, Seattle Children s Hospital, Seattle, WA, USA Electronic address
    Paediatr Respir Rev 14:152-6. 2013
  2. pmc Factors associated with mortality in patients with tuberculosis
    David J Horne
    Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
    BMC Infect Dis 10:258. 2010
  3. doi request reprint A story of success: continuous quality improvement in cystic fibrosis care in the USA
    Bradley S Quon
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA
    Thorax 66:1106-8. 2011
  4. pmc Clinical trial participants compared with nonparticipants in cystic fibrosis
    Christopher H Goss
    University of Washington Medical Center, Campus Box 356522, 1959 N E Pacific, Seattle, WA 98195, USA
    Am J Respir Crit Care Med 173:98-104. 2006
  5. ncbi request reprint Laboratory parameter profiles among patients with cystic fibrosis
    Christopher H Goss
    Department of Medicine, University of Washington Medical Center, Seattle, WA 98195, USA
    J Cyst Fibros 6:117-23. 2007
  6. pmc Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis
    Christopher H Goss
    Department of Medicine, University of Washington Medical Center, Campus Box 356522, 1959 NE Pacific, Seattle, Washington 98195, USA
    Thorax 62:360-7. 2007
  7. pmc Patient-reported outcomes in cystic fibrosis
    Christopher H Goss
    Department of Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA
    Proc Am Thorac Soc 4:378-86. 2007
  8. ncbi request reprint Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis
    C H Goss
    Department of Medicine, University of Washington, Seattle WA 98195, United States
    J Cyst Fibros 7:147-53. 2008
  9. doi request reprint Patient-reported respiratory symptoms in cystic fibrosis
    C H Goss
    Department of Medicine, University of Washington, Seattle, WA, USA
    J Cyst Fibros 8:245-52. 2009
  10. doi request reprint Review: Staphylococcus aureus and MRSA in cystic fibrosis
    Christopher H Goss
    Department of Medicine, University of Washington, Seattle WA, USA
    J Cyst Fibros 10:298-306. 2011

Detail Information

Publications48

  1. doi request reprint Comparative effectiveness research - what is it and how does one do it?
    Christopher H Goss
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington, Seattle, WA, USA Division of Pulmonary Medicine, Department of Pediatrics, Seattle Children s Hospital, Seattle, WA, USA Electronic address
    Paediatr Respir Rev 14:152-6. 2013
    ....
  2. pmc Factors associated with mortality in patients with tuberculosis
    David J Horne
    Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
    BMC Infect Dis 10:258. 2010
    ..Known risk factors for death following a diagnosis of tuberculosis may not be applicable to current U.S. cases. We evaluated the factors associated with all-cause mortality in patients with tuberculosis in Washington State...
  3. doi request reprint A story of success: continuous quality improvement in cystic fibrosis care in the USA
    Bradley S Quon
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA
    Thorax 66:1106-8. 2011
    ..CQI represents one model to achieve quality improvement (QI) and has long been recognized as a key to success in the manufacturing industry with companies like Toyota leading the way...
  4. pmc Clinical trial participants compared with nonparticipants in cystic fibrosis
    Christopher H Goss
    University of Washington Medical Center, Campus Box 356522, 1959 N E Pacific, Seattle, WA 98195, USA
    Am J Respir Crit Care Med 173:98-104. 2006
    ..The randomized clinical trial has been an important tool for expanding our knowledge of disease. This study is the first to compare trial participants to the entire eligible population...
  5. ncbi request reprint Laboratory parameter profiles among patients with cystic fibrosis
    Christopher H Goss
    Department of Medicine, University of Washington Medical Center, Seattle, WA 98195, USA
    J Cyst Fibros 6:117-23. 2007
    ..Laboratory-specific normal reference ranges may not accurately reflect what is abnormal but clinically insignificant among CF patients...
  6. pmc Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis
    Christopher H Goss
    Department of Medicine, University of Washington Medical Center, Campus Box 356522, 1959 NE Pacific, Seattle, Washington 98195, USA
    Thorax 62:360-7. 2007
    ..This review provides a summary of the pathophysiology, clinical epidemiology and microbial epidemiology of a CF pulmonary exacerbation...
  7. pmc Patient-reported outcomes in cystic fibrosis
    Christopher H Goss
    Department of Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA
    Proc Am Thorac Soc 4:378-86. 2007
    ....
  8. ncbi request reprint Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis
    C H Goss
    Department of Medicine, University of Washington, Seattle WA 98195, United States
    J Cyst Fibros 7:147-53. 2008
    ..Centralized spirometry may significantly improve quality of spirometry and reduce variability of this outcome measure in clinical trials in cystic fibrosis (CF)...
  9. doi request reprint Patient-reported respiratory symptoms in cystic fibrosis
    C H Goss
    Department of Medicine, University of Washington, Seattle, WA, USA
    J Cyst Fibros 8:245-52. 2009
    ..Cystic fibrosis (CF) specific patient-derived and reported symptom tools are critical steps toward evaluating the outcomes of new therapies for CF...
  10. doi request reprint Review: Staphylococcus aureus and MRSA in cystic fibrosis
    Christopher H Goss
    Department of Medicine, University of Washington, Seattle WA, USA
    J Cyst Fibros 10:298-306. 2011
    ..aureus) is one of the earliest bacteria detected in infants and children with cystic fibrosis (CF). The rise of methicillin resistant S. aureus (MRSA) in the last 10 years has caused a lot of attention to this organism...
  11. ncbi request reprint Update on cystic fibrosis epidemiology
    Christopher H Goss
    Department of Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA
    Curr Opin Pulm Med 10:510-4. 2004
    ..This review is not meant to be comprehensive, but highlights selected studies, many of which have particular relevance to the growing number of older CF patients...
  12. pmc Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis
    C H Goss
    Department of Medicine, University of Washington Medical Center, Seattle, WA 98195, USA
    Thorax 59:955-9. 2004
    ..Stenotrophomonas maltophilia (SM) is a Gram-negative non-fermenting bacteria cultured from the sputum of patients with cystic fibrosis (CF). To date, no information is available regarding the effect of this organism on lung function in CF...
  13. ncbi request reprint The effect of pregnancy on survival in women with cystic fibrosis
    Christopher H Goss
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington Medical Center, Seattle, WA 98195, USA
    Chest 124:1460-8. 2003
    ..Patients with cystic fibrosis (CF) are currently living to their fourth decade and are making reproductive decisions. Information concerning the reproductive health of women with CF has been limited to small or single-center studies...
  14. ncbi request reprint Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital
    Christopher H Goss
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington School of Medicine, Medical Center Campus, Box 356522, 1959 N E Pacific, Seattle, WA 98195, USA
    Chest 124:2148-55. 2003
    ..A newly validated CAP outcomes prediction rule developed by Fine and colleagues has been advocated as a guide to hospitalization decisions...
  15. ncbi request reprint The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases
    C H Goss
    Department of Medicine, University of Washington, School of Medicine, Seattle, WA, USA
    Adv Drug Deliv Rev 54:1505-28. 2002
    ..The Cystic Fibrosis Therapeutics Development Network represents a network that has met this challenge and will continue to provide a venue for the safe and efficient conduct of clinical trials in Cystic Fibrosis...
  16. ncbi request reprint Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis
    Christopher H Goss
    Department of Medicine, University of Washington, Seattle, WA 98195, USA
    Am J Respir Crit Care Med 169:816-21. 2004
    ..91-1.93; 95% CI). Annual average exposures to particulate air pollution was associated with an increased risk of pulmonary exacerbations and a decline in lung function, suggesting a role of environmental exposures on prognosis in CF...
  17. ncbi request reprint Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis
    Christopher H Goss
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington Medical Center, Campus Box 356522, 1959 N E Pacific, Seattle, WA 98195, USA
    Am J Respir Crit Care Med 166:356-61. 2002
    ..89 (95% confidence interval, 0.75-1.05). Although patients with CF who acquire S. maltophilia have more advanced disease than those who do not acquire this organism, detection does not independently affect short-term survival (3 years)...
  18. ncbi request reprint Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, Washington 98105 0371, USA
    Am J Respir Crit Care Med 166:1550-5. 2002
    ..Better clinical predictors of short-term mortality among patients with CF are needed...
  19. pmc Influenza-associated cystic fibrosis pulmonary exacerbations
    Justin R Ortiz
    Division of Pulmonary and Critical Care Medicine, University of Washington Medical Center, Box 356522, 1959 NE Pacific St, Seattle, WA 98195 6522, USA
    Chest 137:852-60. 2010
    ..Although cystic fibrosis (CF) is the most common inherited respiratory disease, the burden of influenza among individuals with CF is not well characterized...
  20. ncbi request reprint A patient with vanishing lung syndrome and remarkable tolerance to high altitude
    Andrew Mark Luks
    Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA 98195 6522, USA
    Med Sci Sports Exerc 39:1891-5. 2007
    ..Such travel may, in fact, be safe as long as the patient has undergone appropriate pretravel evaluation, and we provide recommendations regarding such evaluation in patients with chronic obstructive pulmonary disease...
  21. doi request reprint Out-of-hospital fluid in severe sepsis: effect on early resuscitation in the emergency department
    Christopher W Seymour
    Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington, USA
    Prehosp Emerg Care 14:145-52. 2010
    ..Early identification and treatment of patients with severe sepsis improves outcome, yet the role of out-of-hospital intravenous (IV) fluid is unknown...
  22. pmc Out-of-hospital characteristics and care of patients with severe sepsis: a cohort study
    Christopher W Seymour
    Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA 98104, USA
    J Crit Care 25:553-62. 2010
    ....
  23. pmc Long-term survival after hospitalization for community-acquired and healthcare-associated pneumonia
    Laura M Cecere
    Division of Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, WA 98101, USA
    Respiration 79:128-36. 2010
    ..Elderly patients surviving community-acquired pneumonia (CAP) have subsequent increased mortality. However, little is known regarding long-term survival in younger adults or those with healthcare-associated pneumonia (HCAP)...
  24. ncbi request reprint Lung allocation score for lung transplantation: impact on disease severity and survival
    Cynthia J Gries
    Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA 98195, USA
    Chest 132:1954-61. 2007
    ..The impact of LAS implementation on patient characteristics and survival is unknown...
  25. doi request reprint Development of a predictive model for long-term survival after lung transplantation and implications for the lung allocation score
    Cynthia J Gries
    Department of Medicine, University of Washington, Seattle, WA, USA
    J Heart Lung Transplant 29:731-8. 2010
    ..Validated survival modeling is important for guiding clinical decision-making, case-mix adjustment in comparative effectiveness research and refinement of the lung allocation system (LAS)...
  26. ncbi request reprint CFTR genotype as a predictor of prognosis in cystic fibrosis
    Edward F McKone
    Division of Pulmonary and Critical Care Medicine and Adult Cystic Fibrosis Center, University of Washington Medical Center, Seattle, WA 98195 6522, USA
    Chest 130:1441-7. 2006
    ..STUDY RATIONALE: Certain CFTR genotypes are associated with reduced mortality. The accuracy of using CFTR genotype as a predictor of survival and the mechanisms through which CFTR genotype influences survival are unknown...
  27. pmc Predictors of influenza vaccination in the Cystic Fibrosis Foundation patient registry, 2006 through 2007
    Justin R Ortiz
    Division of Pulmonary and Critical Care Medicine, University of Washington Medical Center, Seattle, WA 98195 6522, USA
    Chest 138:1448-55. 2010
    ..Influenza vaccination is recommended for all persons with cystic fibrosis (CF). Despite this recommendation, no study has been performed to determine factors associated with receipt of influenza vaccination among persons with CF...
  28. ncbi request reprint Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trials
    Heidi Sucharew
    CF Therapeutics Development Network Coordinating Center, Seattle, WA, United States
    Contemp Clin Trials 27:561-70. 2006
    ..The tables published from this study can be used to assist those charged with safety monitoring in CF clinical trials...
  29. pmc Genetic variation in the FAS gene and associations with acute lung injury
    Bradford J Glavan
    Section of Pulmonary Critical Care Medicine, Harborview Medical Center, Seattle, Washington, USA
    Am J Respir Crit Care Med 183:356-63. 2011
    ..Fas (CD95) modulates apoptosis and inflammation and is believed to play an important role in lung injury...
  30. ncbi request reprint Improved survival among young patients with cystic fibrosis
    Michal Kulich
    Department of Biostatistics, University of Washington, Seattle 98195 7232, USA
    J Pediatr 142:631-6. 2003
    ..To investigate age-specific trends in survival among US patients with cystic fibrosis between 1985 and 1999 and to assess whether survival in female patients with cystic fibrosis has improved relative to survival in male patients...
  31. ncbi request reprint Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis
    Moira L Aitken
    Department of Medicine, Division of Pulmonary and Critical Care, University of Washington, Seattle 98195, USA
    Chest 123:792-9. 2003
    ..The hypothesis was that the duration of SI collection would quantitatively and qualitatively alter the content of the induced sputum...
  32. pmc Changes in arterial oxygenation and self-reported oxygen use after lung volume reduction surgery
    Margaret L Snyder
    Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington 98195 6522, USA
    Am J Respir Crit Care Med 178:339-45. 2008
    ..Lung volume reduction surgery (LVRS) is inconsistently reported to improve arterial oxygenation in patients with chronic obstructive pulmonary disease...
  33. doi request reprint Contraceptive practices in women with cystic fibrosis
    Barry J Plant
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington Medical Center, Seattle WA 98195 6522, United States
    J Cyst Fibros 7:412-4. 2008
    ..Despite theoretical concerns regarding efficacy and toxicity, the choices of contraception are similar to those of the general U.S. population...
  34. doi request reprint Pulmonary function in the morbidly obese
    Joshua A Saliman
    Department of Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA
    Surg Obes Relat Dis 4:632-9; discussion 639. 2008
    ..To assess the relationship between lung function tests and clinical characteristics in a cohort of morbidly obese patients undergoing evaluation for bariatric procedures in a university hospital in the United States...
  35. ncbi request reprint Early tumor necrosis factor-alpha release from the pulmonary macrophage in lung ischemia-reperfusion injury
    Babu V Naidu
    Division of Cardiothoracic Surgery, Department of Surgery, University of Washington Medical Center, Seattle 98195, USA
    J Thorac Cardiovasc Surg 127:1502-8. 2004
    ..The present study was undertaken to determine whether the alveolar macrophage is an important source of tumor necrosis factor-alpha in lung ischemia-reperfusion injury and whether suppression of its function protects against injury...
  36. ncbi request reprint Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health
    Patrick A Flume
    Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Am J Respir Crit Care Med 176:957-69. 2007
    ..Hence, it is important that treatments should be recommended on the basis of available evidence of efficacy and safety...
  37. ncbi request reprint Clinician statements and family satisfaction with family conferences in the intensive care unit
    Renee D Stapleton
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, School of Medicine, University of Washington, Seattle, WA, USA
    Crit Care Med 34:1679-85. 2006
    ..In this exploratory analysis, we hypothesized that clinicians' communication behaviors providing emotional support to families during intensive care unit conferences would be associated with increased family satisfaction...
  38. ncbi request reprint Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients
    Drucy Borowitz
    CF Therapeutics Development Network, Seattle, Wash, USA
    Pancreas 32:258-63. 2006
    ..We conducted a phase 1 study of a novel pancreatic enzyme product, TheraCLEC-Total (TCT), a proprietary formulation of microbial-derived lipase, protease, and amylase, to determine its safety and preliminary efficacy in cystic fibrosis...
  39. ncbi request reprint Hospital volume and the outcomes of mechanical ventilation
    Jeremy M Kahn
    Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle 98104, USA
    N Engl J Med 355:41-50. 2006
    ..The relationship between the number of patients admitted (hospital volume) and outcome among patients with critical illnesses is unknown...
  40. ncbi request reprint Incidence of acute lung injury in the United States
    Christopher H Goss
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington Medical Center, Seattle, WA, USA
    Crit Care Med 31:1607-11. 2003
    ..We hypothesized that careful, prospective, protocol-driven case identification that included the milder hypoxemia criterion for ALI would yield incidence numbers greater than previously reported...
  41. ncbi request reprint Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease
    Anthony J Gerbino
    Sections of Pulmonary Critical Care Medicine, Virginia Mason Medical Center, 1100 Ninth Ave, Seattle, WA 98111, USA
    Chest 133:455-60. 2008
    ..We sought to determine the effectiveness of mycophenolate mofetil (MMF) in scleroderma- associated interstitial lung disease (SSc-ILD)...
  42. doi request reprint Alveolar macrophage secretory products augment the response of rat pulmonary artery endothelial cells to hypoxia and reoxygenation
    Anton S McCourtie
    Department of Surgery, Division of Cardiothoracic Surgery, University of Washington Medical Center, Seattle, Washington 98195, USA
    Ann Thorac Surg 85:1056-60. 2008
    ..The aim of this study was to determine whether alveolar macrophage secretory products amplify the response of the endothelial cell using an in vitro model of lung reperfusion injury...
  43. ncbi request reprint Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis
    Christian A Merlo
    The Johns Hopkins University School of Medicine, 1830 E Monument St Fifth Floor, Baltimore, MD 21205, USA
    Chest 132:562-8. 2007
    ..The main objective of the study was to estimate the incidence and identify risk factors for the acquisition of MARPA among individuals with CF...
  44. ncbi request reprint Disease-specific reference equations for lung function in patients with cystic fibrosis
    Michal Kulich
    Department of Probability and Mathematical Statistics, Charles University, Prague, Czech Republic
    Am J Respir Crit Care Med 172:885-91. 2005
    ..There are limitations to comparing the lung function of a patient with CF to that of healthy control subjects, and potential advantages to comparing it to that of other patients with CF...
  45. ncbi request reprint Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis
    Drucy Borowitz
    Women and Children s Hospital of Buffalo, Division of Pediatric Pulmonology, State University of New York at Buffalo, Buffalo, NY 14222, USA
    J Pediatr 149:658-662. 2006
    ....
  46. ncbi request reprint Airway clearance in cystic fibrosis
    Christopher H Goss
    Respir Care 48:20-1. 2003
  47. doi request reprint Factors associated with severe disease in a population of asthmatic children of Bogota, Colombia
    Carlos Rodriguez Martinez
    Department of Pediatric Respiratory Medicine, Clinica Colsanitas, Clinica Infantil Colsubsidio, Bogota, Colombia
    J Asthma 45:141-7. 2008
    ..The aim of this study was to investigate the role of suspected, potential risk factors for asthma severity in a population of children living in urban Bogota...
  48. ncbi request reprint Should we stop using intravenous gentamicin in patients with cystic fibrosis?
    Christopher H Goss
    Thorax 63:479-80. 2008

Research Grants6

  1. Quality of Life in patients with severe Cystic Fibrosis
    Christopher Goss; Fiscal Year: 2007
    ....
  2. Environmental Effects on Lung Function in Cystic Fibrosis Patients
    Christopher Goss; Fiscal Year: 2007
    ..Our proposal will also enhance our understanding of lung growth in CF and represents the initial phase of a program to understand environmental effects on CF lung disease. ..
  3. A pharmacokinetic and safety study of IV gallium nitrate (Ganite) in cystic fibro
    CHRISTOPHER HOOPER GOSS; Fiscal Year: 2010
    ..A pharmacokinetic and safety study of intravenous (IV) Ga in subjects with cystic fibrosis (CF) is being proposed as chronic P. aeruginosa airway infections are the major cause of death in these patients and few treatments exist. ..
  4. Early Intervention in Pulmonary Exacerbation in CF
    Noah Lechtzin; Fiscal Year: 2010
    ..This approach will utilize state of the art, telehealth equipment to improve the assessment and delivery of care to adolescents and adults with CF. ..